ATE296629T1 - Pharmazeutische zusammensetzungen mit nmda- rezeptor-agonist - Google Patents

Pharmazeutische zusammensetzungen mit nmda- rezeptor-agonist

Info

Publication number
ATE296629T1
ATE296629T1 AT01270205T AT01270205T ATE296629T1 AT E296629 T1 ATE296629 T1 AT E296629T1 AT 01270205 T AT01270205 T AT 01270205T AT 01270205 T AT01270205 T AT 01270205T AT E296629 T1 ATE296629 T1 AT E296629T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
receptor agonist
nmda receptor
agonist pharmaceutical
nmda
Prior art date
Application number
AT01270205T
Other languages
English (en)
Inventor
Jinyang Hong
Yesook Kim
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE296629T1 publication Critical patent/ATE296629T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT01270205T 2000-12-13 2001-12-05 Pharmazeutische zusammensetzungen mit nmda- rezeptor-agonist ATE296629T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25537200P 2000-12-13 2000-12-13
PCT/IB2001/002359 WO2002047685A2 (en) 2000-12-13 2001-12-05 Nmda receptor agonist pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE296629T1 true ATE296629T1 (de) 2005-06-15

Family

ID=22968017

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01270205T ATE296629T1 (de) 2000-12-13 2001-12-05 Pharmazeutische zusammensetzungen mit nmda- rezeptor-agonist

Country Status (41)

Country Link
US (2) US6635270B2 (de)
EP (1) EP1347760B1 (de)
JP (1) JP2004515529A (de)
KR (1) KR100533407B1 (de)
CN (1) CN1273135C (de)
AP (1) AP1235A (de)
AR (1) AR035607A1 (de)
AT (1) ATE296629T1 (de)
AU (2) AU1845402A (de)
BG (1) BG107788A (de)
BR (1) BR0116085A (de)
CA (1) CA2431172A1 (de)
CZ (1) CZ20031543A3 (de)
DE (1) DE60111265T2 (de)
DO (1) DOP2001000300A (de)
DZ (1) DZ3484A1 (de)
EA (1) EA006489B1 (de)
EC (1) ECSP034655A (de)
EE (1) EE200300284A (de)
ES (1) ES2239648T3 (de)
GE (1) GEP20053568B (de)
HR (1) HRP20030473A2 (de)
HU (1) HUP0400645A2 (de)
IL (1) IL155810A0 (de)
IS (1) IS6811A (de)
MA (1) MA26970A1 (de)
MX (1) MXPA03005257A (de)
NO (1) NO20032678L (de)
NZ (1) NZ525742A (de)
OA (1) OA12414A (de)
PA (1) PA8534901A1 (de)
PE (1) PE20020710A1 (de)
PL (1) PL362080A1 (de)
PT (1) PT1347760E (de)
SK (1) SK6982003A3 (de)
TN (1) TNSN01173A1 (de)
UA (1) UA73619C2 (de)
UY (1) UY27068A1 (de)
WO (1) WO2002047685A2 (de)
YU (1) YU41103A (de)
ZA (1) ZA200303892B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811272C (en) 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CL2007003410A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
CN101317844B (zh) * 2007-06-08 2010-11-17 章劲夫 化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
WO2011100585A1 (en) 2010-02-11 2011-08-18 Joseph Moskal Secondary structure stabilized nmda receptor modulators and uses thereof
CN102586243A (zh) * 2012-03-08 2012-07-18 中国人民解放军军事医学科学院放射与辐射医学研究所 一种预防电磁辐射致脑损伤的标志物
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9758525B2 (en) 2013-01-29 2017-09-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
EP2951186B1 (de) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam-nmda-rezeptormodulatoren und verwendungen davon
PE20151416A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
KR102410989B1 (ko) 2013-01-29 2022-06-17 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
JP2016506962A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
CN105934247A (zh) 2013-12-23 2016-09-07 株式会社三养生物制药 包含帕洛诺司琼的药物组合物
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
KR102465758B1 (ko) 2016-08-01 2022-11-09 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en) * 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
DK0843661T3 (da) * 1995-08-11 2002-07-22 Pfizer (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethansulfonat-trihydrat
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

Also Published As

Publication number Publication date
KR100533407B1 (ko) 2005-12-02
CZ20031543A3 (cs) 2004-06-16
DZ3484A1 (fr) 2002-06-20
JP2004515529A (ja) 2004-05-27
US20020111366A1 (en) 2002-08-15
DOP2001000300A (es) 2002-05-30
WO2002047685A3 (en) 2002-08-15
HUP0400645A2 (hu) 2004-06-28
AP2001002376A0 (en) 2001-12-31
ZA200303892B (en) 2004-05-20
MA26970A1 (fr) 2004-12-20
PA8534901A1 (es) 2002-08-26
AR035607A1 (es) 2004-06-16
UY27068A1 (es) 2002-07-31
US6635270B2 (en) 2003-10-21
NO20032678D0 (no) 2003-06-12
PL362080A1 (en) 2004-10-18
DE60111265T2 (de) 2006-05-04
HK1059575A1 (en) 2004-07-09
EP1347760A2 (de) 2003-10-01
ECSP034655A (es) 2003-07-25
EA006489B1 (ru) 2005-12-29
TNSN01173A1 (fr) 2005-11-10
AP1235A (en) 2004-01-06
WO2002047685A2 (en) 2002-06-20
IL155810A0 (en) 2003-12-23
UA73619C2 (en) 2005-08-15
IS6811A (is) 2003-05-08
KR20030070060A (ko) 2003-08-27
DE60111265D1 (de) 2005-07-07
OA12414A (en) 2006-04-18
YU41103A (sh) 2006-05-25
NO20032678L (no) 2003-06-12
CN1479617A (zh) 2004-03-03
BR0116085A (pt) 2003-12-23
SK6982003A3 (en) 2004-08-03
CN1273135C (zh) 2006-09-06
PT1347760E (pt) 2005-09-30
EA200300514A1 (ru) 2003-10-30
US20040039022A1 (en) 2004-02-26
AU2002218454B2 (en) 2005-10-27
ES2239648T3 (es) 2005-10-01
CA2431172A1 (en) 2002-06-20
AU1845402A (en) 2002-06-24
GEP20053568B (en) 2005-07-11
NZ525742A (en) 2005-07-29
EP1347760B1 (de) 2005-06-01
BG107788A (bg) 2004-01-30
HRP20030473A2 (en) 2005-04-30
MXPA03005257A (es) 2003-09-25
PE20020710A1 (es) 2002-08-09
EE200300284A (et) 2003-10-15

Similar Documents

Publication Publication Date Title
ATE296629T1 (de) Pharmazeutische zusammensetzungen mit nmda- rezeptor-agonist
DE60127002D1 (de) Pharmazeutische zusammensetzung
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
ATE279961T1 (de) Neue pharmazeutische zusammensetzung
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
ITTO20010008A0 (it) Formulazione farmaceutica
DE60037277D1 (de) Adenosinrezeptor-agonist oder antagonist enthaltende pharmazeutische zusammensetzungen
ATE404180T1 (de) Geschmacksmaskierte pharmazeutische partikel
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
EP1411904A4 (de) Pharmazeutische zusammensetzung mit verzögerter freisetzung
DE60122495D1 (de) TRANS-N-i4-(4-HYDROXYPHENYL)CYCLOHEXYLö-3-PHENYLPROPIONAMID ALS SUBTYP-SELEKTIVER NMDA REZEPTOR ANTAGONIST
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
IL161997A0 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
ATE327759T1 (de) Pharmazeutische zusammensetzung mit verlungerter freisetzung
ATE366128T1 (de) Pharmazeutische zusammensetzung
ATE348599T1 (de) Pharmazeutische dronedaron-zusammensetzung für die parenterale verabreichung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DE10107261B4 (de) Pharmazeutische Zusammensetzung
DK1347760T3 (da) Farmaceutiske kompositioner med NMDA receptor agonister
DK1450770T3 (da) Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1347760

Country of ref document: EP

REN Ceased due to non-payment of the annual fee